IFN-γ elevation is one of the indicators of successful treatment in active tuberculosis (TB) 2. infection due to macrophage and Th-1 activation in inducing autophagy process. However, 3. IL-10 also inhibits interferon-mediated mycobactericid activities by blocking IFN-γ 4. signaling pathways in autophagy. Therefore, ratio IFN-γ / IL-10 has to be greater than 1 5. (>1) then IFN-γ remains has anti-mycobacterium. Metformin (MET) is a potent 6. combination drug to elevate anti-TB efficacy and able to regulate inflammation.
INTRODUCTION

Mycobacterium tuberculosis (M. tuberculosis) infection or known by TB infection is a
16. leading cause of global morbidity and mortality thus, requiring long-term therapy 1,2 .
17. There are five phases of M.tuberculosis infection and divided into two main phase. Firstly 2 18. is invasion phase (phase 1-2) and secondly is immunological phase, this phase is happened 19 . due to the immunology response during interaction of M. tuberculosis and host (phases 3-20. 5) 3 . Invasion phase occurs when M. tuberculosis reaches the pulmonary alveoli and 21 . becomes colony in the lung with its ability to avoid the phagocytosis. In phase 2, 22 . M.tuberculosis multiplies in immature nonactivated macrophages to form a lesion called 23 . tubercle. In invasion phase, anti TB works well to eliminate M. tuberculosis. However, the 24 . efficacy of anti TB reduce in immunology phase, which the host body starts limit M. 25 . tuberculosis by developing caseous necrosis as immune response against tuberculin-like 26. antigens released by M.tuberculosis in phase 3, then becomes liquefaction phase in phase 27. 4 to 5 to limited tuberculosis extracellular multiplication 3, 4 . The aimed of anti-TB 28. therapy is curing patients, preventing death, preventing recurrence, cutting off transmission 29. chains and preventing germ resistance by eradication of M.tuberculosis. The effectiveness 30. of rifampicin, isoniazid, pyrazinamide and ethambutol is influenced by host immune 31. response 5, 6 .Therefore, new approach is needed to enhance anti TB efficacy during 32. immunology phase. One of offered suggestion was compiled MET during intensive phase 33. of anti-TB therapy.
34.
35. Metformin hydrochloride (MET), biguanide, use in type 2 diabetes mellitus by 1) 36. inhibiting the production of hepatic glucose; 2) reducing intestinal glucose absorption; and 37. 3) improving glucose uptake and utilization 5, 7, 8 . MET is known affecting inflammation 38. mediators, both pro-inflammation, such IFN-γ, IL-β and also anti-inflammation such IL-10 39. [8] [9] [10] . Interferon (IFN)-γ is a potent cytokine that indicates antimicrobial effect and also 40. modulates the production or activities of several cytokines and chemokines [11] [12] [13] . IFN-41. γ activates macrophages and dendritic cells to perform autophagy to M. Tuberculosis, and 42. diminished of IFN-γ relates to anti-tuberculosis therapy failure 14-18 . 43. 
52.
53. The levels of IFN-γ and IL-10 was measured before and after this observation period and 54. as a clinical result, we also evaluated the smear reversion in DM-TB coinfection patients in 55. both groups. 
Diagnosis and Management Therapy
61.
62. Patients diagnosed with TB were registered and treated with anti-TB for 6 months in 63. accordance to WHO guidelines 19, 20 . Insulin use for achieving good glycaemic control 64. in the patients in this study. These following drugs were used: MET (Metformin (R) ), insulin 65. (Humulin (R) ), rifampicin (RIF), isoniazid (INH), pyrazinamide (PYR), ethambutol (ETH). 66. MET were given 1000 -1500 mg in the divided daily dose for at least two months or during 67. the intensive phase of anti-TB therapy.
Acid Fast Bacilli Smears (AFB) Smears
68. Sputum smears were examined two times : 1) before treatment in order to diagnose and 69. 2) after the intensive phase of anti-TB treatment in order to do evaluation. 80. All the basic conditions in both groups were homogeneous (p > 0,05) (as seen in table 1).
81.
82. In order to prevent MET associated lacto acidosis (MALA) during MET therapy in this 83. study, all patients has been determined as mention at enrolled patients criterias (data was 84. as seen in table 1). Moreover, there was no incidence of lactic acidosis event during this 85. observation period 21 . 87. During observation weeks (intensive phase of anti-TB therapy), we also obtained fasting 88. blood sugar (FBS) levels periodically and the FBS levels were also similar in both groups 89. (as seen in Figure 1 ). This data show that IFN-γ and IL-10 elevation in this study might be 90. not directly influenced by hyperglycemia condition. Table 2 shows that prior to the intensive phase of anti-TB 93. therapy none of the subjects were having negative AFB in both groups. The highest number 
91.
For sputum smears, as seen in
105.
106.
Using Wilcoxon-Mann Whitney, nonparametric statistical test, figure 2 shows that 107. IFN-γ level before treatment between MET group and non MET group were alike 108. (p>0,005), thus it shows that patients in both groups, before treatment, were in the 109. similar stage of IFN-γ. The differences before and after observation period was 6 110. significant in MET group (p<0,005) while in non MET group was not. Referring to 111. negative AFB in MET group after 2 months intensive therapy (as seen in figure 2 ), it supports that IFN-γ has effect as mycobactericid.
112.
113. 3.2.2 IL-10. . IL-10 has ability to inhibit the Th-1pro-inflammation cytokines, including 114. IFN-γ [23] [24] [25] . Using Wilcoxon-Mann Whitney, nonparametric statistical test, figure 3 115. shows that IL-10 level before treatment between MET group and non MET group were 116. alike (p>0,005), thus it shows that patients in both groups, before treatment, were in the 117. similar stage of IL-10. Although IL-10 level was increased, the differences before and 118. after observation period was not significant between MET and nongroup (p>0,005).
119.
120. 3.2.3 Ratio IFN-γ / IL-10. Ratio IFN-γ / IL-10 shows that immune processes inside the 121. host were more dominated by pro-inflammatory or anti-inflammatory cytokines after 122. intensive phase of anti-TB with or without MET therapy. Whenever the IFN-γ / IL-10 123. ratio is greater than 1 (>1), thus the host's immunity defense system was dominated by 124. pro-inflammation condition 26 .
125.
126.
Using Wilcoxon-Mann Whitney, table 3 shows that ratio IFN-γ / IL-10 were not 127. significant difference before and after the intensive phase of anti-TB therapy between 128. MET and non MET group (p>0,005). However, IFN-γ / IL-10 ratio difference variation 129. after MET combined anti-TB and insulin was narrower than non MET group.
DISCUSSION
130.
IFN-γ is the chief cytokine involved in the protective immune response against 131. mycobacterial infection 11, 27, 28 . The main function of IFN-γ is macrophage and 132. dendritic cells activation, thus in this study autophagy marker was also high 21 and it 7 133. referred to its mycobactericid functions. Predominantly IFN-γ is also contributed to less 134. severe forms of pulmonary TB 23 . Moreover, IFN-γ also enhances the antigen pre 135. sentation through the induction of the expression of molecules from the major 136. histocompatibility complex (MHC) class I and class II and promoting the differentiation 137. of CD4 T lymphocytes to the Th1 subpopulation 11, 22 . Furthermore as conclusion in 138. this study MET associated to inflammation regulatory in DM-TB coinfection patients.
However, IFN-γ relates to CD8 T-lymphocytes or cytotoxic T-cells also contributes to
140. lung tissue damaged, thus IFN-γ activity needs to be controlled 22, 23 .
141.
142. IL-10 a major anti-inflammatory cytokines plays important role in metabolic disorder 143. such diabetes due its affect to insulin sensitivity 29 . IL-10 is produced by macrophages 144. and Th-2 during M. tuberculosis infection It suppresses macrophage function and 145. inhibits pro-inflammation cytokines such IFN-γ, TNF-σ and IL-1β. The increase in IL-146. 10 levels appears to support the mycobacterial survival in the host 23 due to the 147. inhibition of autophagy targeting signals through IL-10 activated SOCS3, and then, 148. SOCS3 inhibits the Janus kinase-2 (Jak2)/signal transducer and activator of transcription 149. (Stat) pathway in activating macrophage autophagy 27, 28 . In this study, the increasing 150. of IL-10 may happen not only due to macrophage related Th-2 activation but also due 151. to insulin attenuated anti-inflammation regulatory [29] [30] [31] [32] .
152.
153.
Based on this result, MET therapy may consider as new strategy in enhancing anti 154. TB efficacy due to its two main ability : 1) MET controlled IL-10 secretion thus alter 155. host immune response against TB infection; and; 2) MET also affects to insulin 156. sensitivity thus enhanced insulin therapy.
157.
158.
Regulating pro-inflammatory and anti-inflammatory cytokines is a critical role in the
